EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis

Lukas Burghart, Sonja Treiber, David Bauer, Emina Halilbasic, Benedikt S Hofer iD, Mattias Mandorfer iD, Michael Gschwantler, Caroline Schwarz, Michael Trauner, Thomas Reiberger iD, Albert F Stättermayer

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70349 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, 2026. Written by Lukas Burghart and 10 co-authors. Institution: Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria. Major MEDLINE topics: Hepatitis, Autoimmune, Hypertension, Portal. Cited 2 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Aims Autoimmune hepatitis (AIH) may progress to advanced chronic liver disease (ACLD) with clinically significant portal hypertension (CSPH). In this study, we evaluated the prevalence of different clinical CSPH features and their prognostic impact regarding decompensation, liver transplantation (LTX) and death in patients with AIH.

Method

Patients with confirmed AIH diagnosis (sIAIHG‐Score ≥ 6) managed at the Vienna General Hospital between 2005 and 2023 were retrospectively analysed.

Results

Among 271 included patients (76.4% female) with AIH, n = 60 (22.1%) presented clinical features of CSPH at diagnosis. During a median follow‐up of 7.2 (IQR 2.9–12.7) years, the proportion with CSPH features increased to n = 104 (38.4%). In a multivariable cox regression analysis, both compensated (aHR: 5.77, 95% CI: [1.47–22.71], p = 0.012) and decompensated features of CSPH (aHR: 15.73, 95% CI: [4.17–59.33], p < 0.0001) were associated with an increased risk of LTX/death, whereas complete biochemical response and higher albumin levels were identified as protective factors. The BAVENO‐VII criteria for ruling‐out CSPH (liver stiffness < 15 kPa and platelet count ≥ 150 G/L) identified AIH patients with a negligible 10Y cumulative incidence of hepatic decompensation (0.8%) and a favourable 10Y transplant‐free survival (97.8%). Overall, n = 16 (5.9%) patients died, with n = 10 deaths caused by CSPH‐related complications.

Conclusion

In patients with AIH, clinical features of CSPH reflect the risk of future hepatic decompensation and mortality. Hence, regular screening for CSPH in AIH patients seems warranted to ensure timely initiation of adequate CSPH‐directed treatment.

Subjects

MeSH terms (MEDLINE)

Hepatitis, AutoimmuneHypertension, PortalHumansFemaleMaleMiddle AgedRetrospective StudiesPrognosisAdultLiver Transplantation

Author keywords

ascitesautoimmune hepatitisliver stiffnessplatelet countportal hypertensionsplenomegalyvarices

Authors and institutions

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Klinik Ottakring, Wiener Gesundheitsverbund, Vienna, Austria.
  • Rare Liver Diseases (RALID) Centre of the ERN RARE-LIVER, At the Vienna General Hospital, Vienna, Austria.
  • Vienna Hepatic Hemodynamic Laboratory, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Christian Doppler Lab for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria.
  • Sigmund Freud University, Vienna, Austria.

ORCID profiles: Benedikt S Hofer, Mattias Mandorfer, Thomas Reiberger

Cite

APA

Burghart, L., Treiber, S., Bauer, D., Halilbasic, E., Hofer, B. S., Mandorfer, M., Gschwantler, M., Schwarz, C., Trauner, M., Reiberger, T., & Stättermayer, A. F. (2026). Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70349

Vancouver

Burghart L, Treiber S, Bauer D, Halilbasic E, Hofer BS, Mandorfer M, et al. Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70349

BibTeX
@article{Burghart2026,
  author = {Burghart, Lukas and Treiber, Sonja and Bauer, David and Halilbasic, Emina and Hofer, Benedikt S and Mandorfer, Mattias and Gschwantler, Michael and Schwarz, Caroline and Trauner, Michael and Reiberger, Thomas and Stättermayer, Albert F},
  title = {Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70349}
}
Start for free →